ArticleRegenerative medicine2024
Bone marrow aspirate concentrate for the treatment of fifth metatarsal head stress fracture: a case report.
Article in Regenerative medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bedside manufacturing of engineered stem cells using gene therapy foam.Molecular therapy. Methods & clinical development · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metatarsal head stress fractures pose treatment challenges with no established consensus. In this article, we introduce a percutaneous treatment involving autologous bone marrow aspirate concentrate (BMAC) injection without surgical fixation in a 21-year-old basketball player with a stress fracture of the right fifth metatarsal head. He underwent this procedure following unsuccessful 8 months of conservative treatment. Twelve weeks after the procedure, a CT scan confirmed complete healing, facilitating his return to sports. This innovative method offers a promising alternative, avoiding the associated morbidity of surgical intervention. Further research, comparing refracture rates with surgical options, is warranted to inform treatment decisions for this uncommon injury and validate the efficacy of percutaneous BMAC injection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.